Risk factors
Cingulate (CING) risk factors
Item 1A of every Cingulate Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors82 risks3 new3 dropped14 reworded
Cingulate submitted an NDA for its lead drug CTx-1301 with a PDUFA target date of May 31, 2026. The FDA issued a Form 483 with three observations for the CDMO facility in February 2026. The company established commercial partnerships with Indegene and IQVIA for CTx-1301 market launch.
Filed Mar 18, 2026 - FY2024 10-K risk factors82 risks
Cingulate is a clinical-stage biopharmaceutical company facing going concern doubts and needing additional capital to survive.
Filed Mar 27, 2025